Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T02:25:34.160Z Has data issue: false hasContentIssue false
  • English
  • Français

Hypofractionated volumetric modulated arc therapy with SIB adjuvant to breast preservation surgery: retrospective experience from a Regional Cancer Centre in Eastern India

Published online by Cambridge University Press:  29 April 2019

Ashwin Mohandas Pallath ,
Debarshi Lahiri Open the ORCID record for Debarshi Lahiri [Opens in a new window] ,
Biplab Misra ,
Sanjoy Roy ,
Tapas Maji ,
Dilip Kumar Ray  and
Dillip Kumar Misra
Ashwin Mohandas Pallath
Affiliation:
Department of Radiation Oncology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
Debarshi Lahiri*
Affiliation:
Department of Radiation Oncology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
Biplab Misra
Affiliation:
Department of Radiation Oncology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
Sanjoy Roy
Affiliation:
Department of Radiation Oncology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
Tapas Maji
Affiliation:
Department of Radiation Oncology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
Dilip Kumar Ray
Affiliation:
Department of Medical Physics, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
Dillip Kumar Misra
Affiliation:
Department of Medical Physics, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, Pin-700026, India
*
Author for correspondence: Debarshi Lahiri, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, West Bengal, 700026, India. E-mail: debarshil@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The incidence of breast cancer has surpassed cervical cancer in India and it has now become the most common cancer in women. Multiple randomised studies have reported low α/β value in the range of 3–4 for breast cancer, which predict a potential radiobiological advantage for hypofractionated radiotherapy resulting in such schedules becoming standard in many centers with reduction in overall treatment time. Volumetric modulated arc therapy (VMAT) is a novel technique of delivering radiotherapy that reduces treatment delivery time, requires less monitor units (MU) and offers good conformity. The mean dose to normal tissue may be minimised using this technique although there will be inferior sparing if we consider the low-dose volume such as V5, the effect of which is not quantifiable yet.

Aim:

Reporting acute toxicity, cosmetic effects, and quality of life in patients of early breast cancer treated with adjuvant hypofractionated VMAT with SIB.

Material and Methods:

The records of 44 patients registered at the hospital between August 2014 and December 2015 were included in this analysis. Acute toxicities were analysed using CTCAE v4.03. Cosmetic outcomes were assessed using Harvard scale, while quality of life outcomes were assessed using EORTC scales and Health Related quality of life (HRQOL) questionnaires (QLQ-C30 and QLQ-BR23).

Results:

No grade ≥2 skin toxicities were recorded. Breast pain was recorded as Grade 1 in 13·8% patients and Grade 1 fatigue in 18·2%. The maximum haematological abnormality grade recorded was Grade 1. Cosmesis was assessed at the baseline, 6 months, 1 year and 2 years. A total of 88·6% of the patients had an Excellent or good cosmesis at the baseline, which was similar even at 6 months, at 88·7%, improved further at 1 year to 90·9%. At 6 months post radiotherapy, high functional scale QOL scores were noted.

Conclusion:

The technique is associated with minimum acute toxicity, good to excellent cosmesis and acceptable quality of life.

Keywords

breast cancercosmesishypofractionated VMAT-SIBQOLtoxicity
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 18 , Issue 4 , December 2019 , pp. 369 - 374
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bray, F, Ferlay, J, Soerjomataram, I, Siegel, R, Torre, L, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.10.3322/caac.21492CrossRefGoogle ScholarPubMed
Clarke, M, Collins, R, Darby, S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503): 2087–2106. doi: 10.1016/S01406736(05)67887-7.Google ScholarPubMed
Yarnold, J, Ashton, A, Bliss, J et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol 2005; 75 (1): 9–17. doi: 10.1016/j.radonc.2005.01.005.CrossRefGoogle Scholar
START Trialists’ Group, Bentzen, S M, Agrawal, R K et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9 (4): 331–341. doi: 10.1016/S1470-2045(08)70077-9.Google Scholar
Hennequin, C, Dubray, B. [Alpha/beta ratio revisited in the era of hypofractionation]. Cancer Radiother 2013; 17 (5–6): 344–348. doi: 10.1016/jcanrad.2013.06.035.CrossRefGoogle Scholar
Owen, J R, Ashton, A, Bliss, J M et al. Effect of radiotherapy fraction size on tumour control in patients with early stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006; 7 (6): 467–471. doi: 10.1016/S14702045(06)70699-4.CrossRefGoogle ScholarPubMed
START Trialists’ Group, Bentzen, S M, Agrawal, R K et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371 (9618): 1098–1107. doi: 10.1016/S0140-6736(08)60348-7.Google ScholarPubMed
Whelan, T J, Pignol, J P, Levine, M N et al. Long- term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362 (6): 513–520. doi: 10.1056/NEJMoa0906260.CrossRefGoogle ScholarPubMed
Borghero, Y O, Salehpour, M, McNeese, M D et al. Multileaf field-in-field forward- planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: a phantom model comparison. Radiother Oncol 2007; 82 (3): 324–328. doi: 10.1016/j.radonc.2006.10.011.CrossRefGoogle ScholarPubMed
Teh, A Y, Walsh, L, Purdie, T G et al. Concomitant intensity modulated boost during whole breast hypofractionated radiotherapy-a feasibility and toxicity study. Radiother Oncol 2012; 102 (1): 8995. doi: 10.1016/j.radonc.2011.10.015.CrossRefGoogle ScholarPubMed
Scorsetti, M, Alongi, F, Fogliata, A et al. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiat Oncol 2012; 7 (1): 145. doi: 10.1186/1748-717X-7-145.CrossRefGoogle ScholarPubMed
Teoh, M, Clark, C H, Wood, K, Whitaker, S, Nisbet, A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011; 84 (1007): 967–996. doi: 10.1259/bjr/22373346.CrossRefGoogle ScholarPubMed
White, J, Tai, A, Arthur, D et al. Breast cancer atlas for radiation therapy planning: consensus definitions. Radiat Ther Oncol Group, 2011. http://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx.Google Scholar
Anon. 2019. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.Google Scholar
EORTC– Quality of Life. Quality of life of cancer patients | EORTC – quality of life, 2019. https://qol.eortc.org/questionnaire/eortc-qlq-c30.Google Scholar
EORTC– Quality of Life. Breast cancer (update of QLQ-BR23) | EORTC – quality of life, 2019. https://qol.eortc.org/questionnaire/update-qlq-br23.Google Scholar
Formenti, S C, Gidea-Addeo, D, Goldberg, J D et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 2007; 25 (16): 2236–2242. doi: 10.1200/JCO.2006.09.1041.CrossRefGoogle ScholarPubMed
Chadha, M, Vongtama, D, Friedmann, P et al. Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer 2012; 12 (1): 57–62. doi: 10.1016/j.clbc.2011.09.002.CrossRefGoogle ScholarPubMed
Goldstein, D, Bennett, B K, Webber, K et al. Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. J Clin Oncol 2012; 30 (15): 1805–1812. doi: 10.1200/JCO.2011.34.6148.CrossRefGoogle ScholarPubMed
Jagsi, R, Griffith, K A, Boike, T P et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol 2015; 1 (7): 918–930. doi: 10.1001/jamaoncol.2015.2590.CrossRefGoogle Scholar
Harris, J R, Levene, M B, Svensson, G, Hellman, S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 1979; 5 (2): 257–261. doi: 10.1016/03603016(79)90729-6.CrossRefGoogle ScholarPubMed
McDonald, M W, Godette, K D, Whitaker, D J, Davis, L W, Johnstone, P A S. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys 2010; 77 (2): 523–530. doi: 10.1016/j.ijrobp.2009.05.042.CrossRefGoogle ScholarPubMed
Ghannam, A A, Khedr, R A. An accelerated hypofractionated schedule with a daily concomitant boost after breast conservation surgery: the feasibility and toxicity. J Egypt Natl Canc Inst 2016; 28 (1): 39–44. doi: 10.1016/j.jnci.2016.01.002.CrossRefGoogle ScholarPubMed
Fayers, P M, Aaronson, N K, Bjordal, K et al. The EORTC QLQ-C30 Scoring Manual, 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer, 2001.Google Scholar
Mock, V, Dow, K H, Meares, C J et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997; 24 (6): 991–1000.Google ScholarPubMed
Versmessen, H, Vinh-Hung, V, Van Parijs, H et al. Health-related quality of life in survivors of stage I-II breast cancer: randomised trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer 2012; 12 (1): 495.10.1186/1471-2407-12-495CrossRefGoogle Scholar